US Patent Issued to Novartis on Oct. 14 for "Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy" (Swiss, German, American Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,786, issued on Oct. 14, was assigned to Novartis AG (Basel, Switzerland).

"Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy" was invented by Guido Junge (Basel, Switzerland), Michael Kiffe (Efringen-Kirchen, Germany), Jiri Kovarik (Zurich), Richard Stein (Weil am Rhein, Germany) and Frank Waldron-Lynch (Brookline, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of an NLRC4 inflammasomopathy, such as an NLRC4-GOF inflammasomopathy in a subject in need thereof. This...